Reimbursement of innovative pharmaceuticals in English and Spanish hospitals—The example of isavuconazole

• Published in: Mycoses 2021-10, Vol.64 (10), p.1213-1222
• Main Authors: Jeck, Julia, Wingen‐Heimann, Sebastian M., Thielscher, Christian, Kron, Anna, Bonn, Jennifer, Jakobs, Florian, Grau, Santiago, Enoch, David A., Micallef, Christianne, Cornely, Oliver A., Kron, Florian
• Format: Article
• Language: English
• Subjects: Acute myeloid leukemia; Antifungal Agents - economics; Antifungal Agents - therapeutic use; antifungal treatment; Beveridge healthcare system; Cost control; England; Health Care Costs; Hematopoietic stem cells; Hospitals; Humans; Immunosuppressive agents; Inpatients; Insurance, Health, Reimbursement; invasive aspergillosis; invasive fungal diseases; invasive mucormycosis; isavuconazole; Length of stay; Medical innovations; Nitriles - economics; Nitriles - therapeutic use; Patients; Pharmaceuticals; Pyridines - economics; Pyridines - therapeutic use; Reimbursement; Spain; Stem cell transplantation; Triazoles - economics; Triazoles - therapeutic use
• ISSN: 0933-7407; 1439-0507
• DOI: 10.1111/myc.13336

Background Kron et al (Mycoses, 64, 2021, 86) found cost savings for the use of the innovative pharmaceutical isavuconazole in the inpatient setting in Germany (Bismarck‐based healthcare system). Little is known about the reimbursement of innovative pharmaceuticals in the inpatient setting of Beveridge‐based healthcare systems. Objectives The aim of this study was to evaluate the market access process and reimbursement of isavuconazole, exemplary for innovative pharmaceuticals, in England and Spain. Patients/Methods Market access processes of both countries were described. Focussing on typical patient clusters for isavuconazole treatment, reimbursement data regarding inpatients with (i) allogeneic haematopoietic stem cell transplantation or (ii) acute myeloid leukaemia was considered. Data were publicly available and of high topicality (England 2020/2021, Spain 2018). Discounting and a currency conversion to Euro were applied. Results This study showed that market access processes of both countries are broadly similar. Further, full reimbursement of isavuconazole as an innovative pharmaceutical may lead to reduction in resource utilisation. Without medication costs, isavuconazole can thus result in cost savings for both patient clusters due to a reduction in length of stay. Conclusions Expenses for innovative pharmaceuticals may be balanced or even lead to cost savings due to a reduction in length of stay. The latter contributes to a greater patient benefit. For both healthcare system, the analyses highlighted drugs’ cost‐effectiveness and assessing its added value into reimbursement decisions is highly relevant.